ArticleAmerican journal of hematology2022
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Open access · greenAbstract readLetterMulticenter Study
In one paragraph
Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.Blood advances · 2023Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 5 institutions in 2 countries.
Meera MohanMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.ORCID 0000-0002-6913-6526
Melody Renee BecnelThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Urvi A ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Huaying DongMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.
Sravani GundarlapalliMyeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Timothy PetersonJanssen Pharmaceuticals, Beerse, Belgium.
Jennifer S OrozcoJanssen Pharmaceuticals, Beerse, Belgium.
Sandra HorowitzThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Saurabh ChhabraMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.ORCID 0000-0001-9117-8696
Binod DhakalMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.ORCID 0000-0002-4377-9742
Sharmilan ThanendrarajanMyeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0003-2593-411X
Sabarinath Venniyil RadhakrishnanMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.
Samer Al HadidiMyeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0003-4297-8042
Carlyn TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0001-7922-2594
Sham MailankodyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Neha KordeMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-5538-4318
Hani HassounMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sheeba K ThomasThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Krina K PatelThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Elisabet E ManasanchThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.ORCID 0000-0002-0857-176X
Donna M WeberThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Aniko SzaboMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.
Gregory P KaufmanThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Hans C LeeThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.ORCID 0000-0001-8545-3292
Maurizio ZangariMyeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0002-1720-3854
Frits van RheeMyeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0001-9959-1282
Saad Z UsmaniMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Anita D'SouzaMedical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.ORCID 0000-0002-1092-5643
Robert Z OrlowskiThe University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
Carolina SchinkeMyeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.ORCID 0000-0002-2699-1741
The University of Texas MD Anderson Cancer Center · USMemorial Sloan Kettering Cancer Center · USFroedtert Hospital · USWinthrop Rockefeller Foundation · USJanssen (Belgium) · BE
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic Agents, ImmunologicalMultiple MyelomaADP-ribosyl Cyclase 1Antibodies, MonoclonalHumansTreatment OutcomeADP-ribosyl Cyclase 1Antibodies, MonoclonalAntineoplastic Agents, Immunological
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.